#IntensityTherapeutics received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid requirement. There is no immediate impact on the Company’s listing, and $INTS will continue trading on the #Nasdaq Capital Market. Full PR: bit.ly/4pkrD6i

Lew Bender, CEO of #IntensityTherapeutics, joined the pharmaphorum Podcast to discuss how intra-tumoural therapies can kill tumors and trigger an immune response within days, including in cancers that do not respond to #immunotherapy. Full episode: bit.ly/4rS4n1t

$INTS is presenting two posters at SABCS. PS5-08-16 shares early Ph2 INVINCIBLE 4 #TNBC data showing favorable safety, with #INT2306 patients reporting 50% fewer grade 3+ adverse events vs standard neoadjuvant chemo. PS4-10-15 outlines a potential Ph3 study design

#IntensityTherapeutics had a great week at SABCS (#SABCS25), connecting with the #breastcancercommunity. CEO Lew Bender, CMO Ian Walters, and Dr. Andreas Mueller were onsite with our INVINCIBLE-4 poster, sharing our latest work to advance #cancercare. $INTS

#IntensityTherapeutics' CEO, Lew Bender, joins Pharma's Almanac's December roundtable to discuss the rise of #GLP1 therapies and their impact on the pharmaceutical landscape. Read the full roundtable: bit.ly/3YkGNfT $INTS

Happy Holidays from the #IntensityTherapeutics team! Here’s to a joyful season and a healthy year ahead. #INTS #HappyHolidays

In a new expert discussion from Clinical Leader, industry leaders agree that statistical significance alone isn’t enough for real patient benefit. Lew Bender, CEO of $INTS, explains why clinically meaningful endpoints matter. Read the full POV: bit.ly/44UdkNQ #INTS

$INTS' CEO, Lew Bender, explains in #DrugDiscovery Online how INT230-6’s intratumoral approach may offer a safer, more effective alternative to current neoadjuvant regimens for women with early #breastcancer & #TNBC. Read the full feature: bit.ly/4hOkLew #Oncology

#DfuseRxSM is #IntensityTherapeutics' proprietary technology that delivers drug compounds directly into #solidtumors with high absorption. Patented dispersion and cell penetration molecules enable targeted, safer dosing. Learn more: bit.ly/3GYhlaF $INTS #INTS #BioTech

Last week, the $INTS leadership team attended the john Healthcare Conference in San Francisco, where they connected with healthcare investment bankers, analysts, potential strategic pharma partners, and industry peers. #JPM2026 #JPM26

#IntensityTherapeutics delivered meaningful clinical and corporate progress in 2025, including continued advancement of the INVINCIBLE-4 Phase 2 study and peer-reviewed validation of #INT2306. Read more: bit.ly/4qIBe7a $INTS #ClinicalResearch

$INTS' CEO, Lew Bender, joined Ira S. Pastor on the Progress, Potential, and Possibilities podcast to discuss  #Intensity’s intratumoral approach and the science behind #INT2306. Watch or listen to the full episode on YouTube: bit.ly/4pP9pJP

#ICYMI: Lew Bender, CEO of $INTS, shared insights on #Intensity’s intratumoral approach and the differentiation of INT230-6 in a feature with Drug Development & Delivery. Full feature: bit.ly/4q0K0Ot #INT2306 #CancerResearch

On a recent pharmaphorum Podcast, Lew Bender, CEO of #IntensityTherapeutics, shared clinical observations from the INT230-6 Phase 1/2 trial, including encouraging outcomes in #sarcoma that supported the move into Phase 3. Catch up on the full episode: bit.ly/4rS4n1t

This #WorldCancerDay, we stand with patients, families, and caregivers impacted by cancer worldwide. $INTS is advancing a novel intratumoral approach designed to target tumors and activate the immune response to help improve outcomes across #solidtumors. #CancerAwareness

#Breastcancer continues to impact hundreds of thousands, with American Cancer Society estimating over 321,000 new invasive cases in the U.S. in 2026. $INTS is advancing #INT2306 to activate the immune system and improve patient outcomes. Learn more: bit.ly/40ipTjJ

#IntensityTherapeutics is proud to highlight Doranne Frano, our Regulatory Affairs and Quality Control leader, with 40+ years of experience working in pharma, biotech, & regulatory compliance. Learn more about $INTS' leadership team: bit.ly/4krq97F #EmployeeSpotlight

Cancer goes beyond what’s visible. On a recent Progress, Potential, and Possibilities podcast, Lewis Bender discusses how $INTS' intratumoral approach targets both tumors and unseen #cancer cells. Full episode on YouTube: bit.ly/4pP9pJP #BiotechPodcast

This #NationalCancerPreventionMonth underscores the importance of prevention, awareness, and continued progress in #cancercare. $INTS is developing innovative intratumoral therapies designed to activate the immune system and improve outcomes for patients with solid tumors. In a